B
Byoung Chul Cho
Researcher at Yonsei University
Publications - 570
Citations - 23868
Byoung Chul Cho is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 57, co-authored 429 publications receiving 15603 citations. Previous affiliations of Byoung Chul Cho include University Health System & AstraZeneca.
Papers
More filters
Three-year overall survival update from the PACIFIC trial.: 2018 ASCO Annual Meeting Abstracts
Jhanelle E. Gray,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,Alberto Chiappori,Ki Hyeong Lee,Byoung Chul Cho,David Planchard,Luis Paz-Ares,Corinne Faivre-Finn,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu,Scott J. Antonia +19 more
TL;DR: The PACIFIC study as mentioned in this paper showed that durvalumab showed significant improvements versus placebo in the primary endpoints of progression-free survival (HR 0.52; 95% CI, 0.42-0.65).
Journal ArticleDOI
Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1.
Sung Baek Jeong,Raju Dash,Dong-Hyun Kim,Si-eun Lee,Hye In Oh,Sungwoo Jo,Yechan Lee,J. Kim,Seon Ju Park,Dong-kyu Choi,Uk Yeol Moon,Oh-Bin Kwon,Wan Namkung,Sungwoo Lee,Byoung Chul Cho,Joohan Woo,Yohan Seo +16 more
TL;DR: In this paper , a chemical compound that reduces ANO1 protein levels was identified through high-throughput screening, and the authors investigated the molecular mechanisms involved in its effect on NSCLC cells.
Journal ArticleDOI
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Ross A. Soo,J-Y. Han,G. Dimopoulou,Byoung Chul Cho,C.M. Yeo,E. Nadal,Enric Carcereny,J. de Castro,M.A. Sala,R. Bernabé,Linda Coate,M. Provencio,R. Garcia Campelo,Sinead Cuffe,S.M.S. Hashemi,Martin Früh,Barbara Ruepp,H. Roschitzki-Voser,Rolf A. Stahel,Solange Peters +19 more
Journal ArticleDOI
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Byoung Chul Cho,K.H. Lee,Myung-Ju Ahn,S. Lucien Geater,Tran Van Ngoc,Chin-Chou Wang,Eun Kyung Cho,J.S. Lee,Virote Sriuranpong,Q. Bui,Stephen Clarke,S. Kuyama,Kazuhiko Nakagawa,F. Liu,Delyth Clemett,U. Scheuring,Solange Peters,Naiyer A. Rizvi +17 more
TL;DR: Durvalumab and tremelimumab were compared to CT and D vs CT in the MYSTIC trial as discussed by the authors, with a clinically meaningful improvement in overall survival (OS) in patients with tumour cell PD-L1 expression ≥ 25%.
Journal ArticleDOI
1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
Rafal Dziadziuszko,Salvatore Siena,D.S.W. Tan,Byoung Chul Cho,M-J. Ahn,Koichi Goto,P. Garrido-Lopez,Anna F. Farago,Herbert H. Loong,D. Tosi,Thomas John,Juergen Wolf,C-H. Chiu,Stephen V. Liu,Manish R. Patel,A. Drilon,Bethany Pitcher,B. Simmons,Robert C. Doebele +18 more